Testing TQB2922 injection for advanced lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new injection called TQB2922 for people with advanced non-squamous non-small cell lung cancer who have already tried standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have advanced non-squamous non-small cell lung cancer that has been confirmed by a biopsy.
- You must have already tried standard treatments, and they either didn't work or you can't have them anymore.
- You must have at least one tumor that can be measured on a scan (like a CT or MRI).
- You must be generally healthy enough to be up and moving around (ECOG score 0 or 1).
- You must agree to use birth control if you are able to have children, during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 trial tests an experimental drug called TQB2252 for people with advanced cancers that have not responded to standard treatments. The drug blocks a protein called LAG3 to help the immune system attack cancer cells.
This trial is testing a new oral medication called TQB3107 for people with advanced solid tumors (cancer that has spread or cannot be removed). The study aims to see if the drug is safe and how well it works.
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
This trial tests a new drug called TQB2928 combined with a common targeted therapy (a third-generation EGFR TKI) for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective, especially for those whose cancer has progressed after previous treatment.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
This trial tests an experimental oral drug called TQB3002 for people with advanced solid tumors who have run out of standard options. Researchers are learning the best dose and how safe it is, with the hope of controlling or shrinking the cancer.
Hear when a new Advanced Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.